Targeting the gullible

With patents for semaglutide expiring in the not-too-distant future, Novo Nordisk is pulling out all the stops to try to differentiate its version — specifically, Ozempic — from other GLP-1 agonists like tirzepatide. The company launched a new ad campaign, “There’s Only One Ozempic,” trying to capitalize on the fact that “Ozempic” has become sort of the generic name for GLP-1 drugs while pushing the fact that, even though it’s not really different than other GLP-1s, it’s been approved for more conditions. Yeah, whatever.